Study Evaluating Treatment Targets Including Transmural Healing in Adults With Moderate to Severe Crohns Disease Using Vedolizumab
Led by Alimentiv Inc. · Updated on 2026-01-15
304
Participants Needed
69
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatment strategies for adults with moderately to severely active Crohns disease CD. The study focuses on transmural healing TMH, a promising but not yet formal treatment target, assessed using noninvasive intestinal ultrasound IUS. The aim is to determine if treating patients to achieve corticosteroid-free IUS outcomes combined with clinical symptoms and biomarkers improves corticosteroid-free endoscopic remission better than targeting symptoms and biomarkers alone.
Participants will be randomly assigned to one of two treatment groups for 48 weeks. Group 1 aims for corticosteroid-free remission based on IUS outcomes, clinical symptoms, and biomarkers, with specific IUS response assessments at weeks 22 and 30 and a final TMH target at week 38. Group 2 aims for corticosteroid-free clinical and biomarker remission without IUS targets. All participants receive vedolizumab infusions starting with an induction regimen followed by maintenance infusions every 8 weeks, with treatment adjustments at weeks 22, 30, and 38 based on target assessments.
Throughout the study, participants will undergo regular assessments including IUS imaging, symptom evaluations, biomarker testing, and endoscopic scoring up to week 48 and beyond. Key measures include corticosteroid-free endoscopic remission, TMH rates, clinical remission, and biomarker responses. Safety and adverse events will be monitored, with follow-up visits extending to week 96. Participation involves adherence to study visits and treatment schedules to evaluate the impact of different treatment targets on disease activity.
CONDITIONS
Brief Title
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Research Team
E
Elena van Hest
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Usual biologic care (e.g., vedolizumab or other advanced therapy per guidelines)
What it is
Vedolizumab given IV for induction and maintenance, with treatment decisions guided by intestinal ultrasound (IUS) for transmural healing target.
Vedolizumab given IV for induction and maintenance, with targets based on clinical remission plus biomarker remission.
Biologic therapy such as vedolizumab or other advanced biologics initiated to induce and maintain remission in moderate‑to‑severe Crohn’s disease per guidelines.
Role in trial
Intervention arm using ultrasound‑based transmural healing endpoint.
Comparator arm using clinical plus biomarker remission endpoints.
Not part of the randomized comparison but reflects common treatment approach outside trial.
Primary use
To assess whether targeting transmural healing via IUS improves outcomes.
To evaluate outcomes when targeting clinical symptoms and biomarker remission.
Routine induction and maintenance of remission using available biologic agents.
How it is given or performed
Vedolizumab 300 mg IV at Weeks 0, 2, 6, 10 then every 8 weeks, with treatment adjustments at Weeks 22, 30, and/or 38 based on IUS.
Vedolizumab dosing same as above, adjustments based on clinical and biomarker remission.
Biologics like vedolizumab typically initiated and maintained per label; dosing may follow IV or subcutaneous form as clinically indicated.
Evidence status
Trial is ongoing; results on transmural healing versus clinical targets are not yet available.
Trial is ongoing; outcomes comparing clinical plus biomarker target versus IUS target pending.
Advanced biologics including vedolizumab have demonstrated effectiveness in inducing and maintaining remission in moderate‑to‑severe Crohn’s disease.
Important risks
Risks are as per vedolizumab’s known safety profile; trial‑specific safety data not yet available.
Risks align with known vedolizumab safety; no trial‑specific data yet.
Vedolizumab has an acceptable long‑term safety profile among biologics with gut‑selective mechanism.
Important limitations
Results are not yet known and applicability depends on feasibility of IUS‑guided decision making.
Comparative benefit over standard clinical plus biomarker targets is unknown until results are available.
Evidence is based on general remission endpoints and may not capture deeper healing outcomes like transmural healing.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 to 80 years at the time of consent
Moderately to severely active Crohn's disease with specific disease activity scores
Bowel wall thickness greater than 4.0 mm in certain intestinal segments as measured by ultrasound
Biologic-naïve or limited prior exposure to advanced therapies within 5 years
Stable dose of 5-ASA treatment if applicable
Negative pregnancy test and use of effective contraception if of childbearing potential
Able to participate fully in all study procedures
Provided written informed consent
You will not qualify if you...
Previous or current treatment with vedolizumab, etrolizumab, or natalizumab
Exposure to two or more advanced biologic or small molecule therapies for Crohn's disease
Recent changes in oral corticosteroid therapy or high corticosteroid doses at randomization
Inflammation only in areas unreachable by colonoscopy
Certain Crohn's disease complications requiring intervention
Extensive colonic surgery or missing key intestinal segments
Presence of ostomy or ileoanal pouch
Short bowel syndrome
Fibrotic strictures without active inflammation
Abscess larger than 2 cm
Serious diseases or infections that affect safety or participation
Positive tests for certain infections including HIV, hepatitis, tuberculosis, or Clostridioides difficile
Hypersensitivity to vedolizumab or related compounds
Recent live vaccination
Military service, legal restrictions, or close relation to study staff
Pregnancy, lactation, or plans for pregnancy during the study
History of substance abuse affecting compliance
Prior participation in this study with treatment received
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 48 weeks
Participants receive vedolizumab through an induction regimen and maintenance dosing to achieve corticosteroid-free remission targets over 48 weeks.
Multiple visits for infusions at Weeks 0, 2, 6, 10, and every 8 weeks starting Week 14 with assessments at Weeks 14, 22, 30, 38, and 48
Follow-up
Duration - Up to 48 weeks after treatment (through Week 96)
Participants are monitored for safety, clinical response, and biomarker remission following the 48-week treatment period.
Periodic visits for assessments up to Week 96
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Long-term Safety Follow-up of ALLO-ASC-CD in Adults With Crohns Disease Previously Treated in Phase 1 Trial
A Master Protocol Evaluating Multiple Treatments for Adults With Moderately to Severely Active Ulcerative Colitis or Crohns Disease
Real-World Study of Guselkumab Treatment in Adults with Moderate to Severe Ulcerative Colitis or Crohns Disease in Saudi Arabia
Phase 4 Open-Label Study to Measure TREMFYA Levels in Breast Milk of Lactating Women Receiving Treatment
A Study Comparing a Smartphone Application and Human Therapist for Psychological Wellbeing in Adults with Crohns Disease
Evaluation of Rectal Administration of a Specific Probiotic to Improve Gut Health in Adults with Mild-to-Moderate Ulcerative Colitis
Pilot Study Using a Retrograde Tethered Capsule Endomicroscope to Image the Lower Gastrointestinal Tract in Adults
International Real-World Study Evaluating Persistence with Guselkumab in Moderate to Severe Crohns Disease and Ulcerative Colitis
Comparing Guselkumab and Risankizumab Treatments for Moderate to Severe Crohns Disease
A Phase 3b Randomized Study Evaluating Efficacy and Safety
Evaluating the Safety and Effectiveness of Icotrokinra Compared to Placebo in Adults With Moderate to Severe Crohns Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.
Vipul Jairath, Sudheer K Vuyyuru, Guangyong Zou...